Format
Sort by
Items per page

Send to

Choose Destination

Links from PubMed

Items: 1 to 20 of 247

1.

Screening for statin-related toxicity: the yield of transaminase and creatine kinase measurements in a primary care setting.

Smith CC, Bernstein LI, Davis RB, Rind DM, Shmerling RH.

Arch Intern Med. 2003 Mar 24;163(6):688-92.

PMID:
12639201
2.

Differential association between statin exposure and elevated levels of creatine kinase.

Chan J, Hui RL, Levin E.

Ann Pharmacother. 2005 Oct;39(10):1611-6. Epub 2005 Sep 13.

PMID:
16160000
3.

Evaluation of cases of severe statin-related transaminitis within a large health maintenance organization.

Charles EC, Olson KL, Sandhoff BG, McClure DL, Merenich JA.

Am J Med. 2005 Jun;118(6):618-24.

PMID:
15922693
4.

The risk for significant creatine kinase elevation with statins.

Stolcpart RS, Olson KL, Delate T, Rasmussen J, Rehring TF, Merenich JA.

Am J Cardiovasc Drugs. 2010;10(3):187-92. doi: 10.2165/11536130-000000000-00000.

PMID:
20524720
5.

Statin safety: lessons from new drug applications for marketed statins.

Jacobson TA.

Am J Cardiol. 2006 Apr 17;97(8A):44C-51C. Epub 2006 Feb 2.

PMID:
16581328
6.

Muscle symptoms associated with statins: a series of twenty patients.

Soininen K, Niemi M, Kilkki E, Strandberg T, Kivistö KT.

Basic Clin Pharmacol Toxicol. 2006 Jan;98(1):51-4.

7.

Statin-associated myopathy with normal creatine kinase levels.

Phillips PS, Haas RH, Bannykh S, Hathaway S, Gray NL, Kimura BJ, Vladutiu GD, England JD; Scripps Mercy Clinical Research Center.

Ann Intern Med. 2002 Oct 1;137(7):581-5.

PMID:
12353945
8.

Muscle pain and serum creatine kinase are not associated with low serum 25(OH) vitamin D levels in patients receiving statins.

Kurnik D, Hochman I, Vesterman-Landes J, Kenig T, Katzir I, Lomnicky Y, Halkin H, Loebstein R.

Clin Endocrinol (Oxf). 2012 Jul;77(1):36-41. doi: 10.1111/j.1365-2265.2011.04321.x.

PMID:
22211469
9.

Monitoring statin safety in primary care.

Tragni E, Filippi A, Mazzaglia G, Sessa E, Cricelli C, Catapano AL.

Pharmacoepidemiol Drug Saf. 2007 Jun;16(6):652-7.

PMID:
17300133
10.

Low myopathy rates associated with statins as monotherapy or combination therapy with interacting drugs in a group model health maintenance organization.

Shanahan RL, Kerzee JA, Sandhoff BG, Carroll NM, Merenich JA.

Pharmacotherapy. 2005 Mar;25(3):345-51.

PMID:
15843281
11.

Meta-analysis of drug-induced adverse events associated with intensive-dose statin therapy.

Silva M, Matthews ML, Jarvis C, Nolan NM, Belliveau P, Malloy M, Gandhi P.

Clin Ther. 2007 Feb;29(2):253-60.

PMID:
17472818
12.

Impact of statin dosing intensity on transaminase and creatine kinase.

Dale KM, White CM, Henyan NN, Kluger J, Coleman CI.

Am J Med. 2007 Aug;120(8):706-12.

PMID:
17679130
13.

Managing statin myopathy.

Venero CV, Thompson PD.

Endocrinol Metab Clin North Am. 2009 Mar;38(1):121-36. doi: 10.1016/j.ecl.2008.11.002. Review.

PMID:
19217515
14.

Managing statin-induced muscle toxicity in a lipid clinic.

Blaier O, Lishner M, Elis A.

J Clin Pharm Ther. 2011 Jun;36(3):336-41. doi: 10.1111/j.1365-2710.2011.01254.x. Epub 2011 Mar 18.

PMID:
21414023
15.

Final conclusions and recommendations of the National Lipid Association Statin Safety Assessment Task Force.

McKenney JM, Davidson MH, Jacobson TA, Guyton JR; National Lipid Association Statin Safety Assessment Task Force.

Am J Cardiol. 2006 Apr 17;97(8A):89C-94C. Epub 2006 Feb 28.

PMID:
16581336
16.

Safety and statin therapy: reconsidering the risks and benefits.

Gotto AM Jr.

Arch Intern Med. 2003 Mar 24;163(6):657-9. No abstract available.

PMID:
12639194
17.

Risks associated with statin therapy: a systematic overview of randomized clinical trials.

Kashani A, Phillips CO, Foody JM, Wang Y, Mangalmurti S, Ko DT, Krumholz HM.

Circulation. 2006 Dec 19;114(25):2788-97. Epub 2006 Dec 11. Review.

18.
19.

Reversible myopathy after statin therapy in patients with normal creatine kinase levels.

Bennett WE, Drake AJ 3rd, Shakir KM.

Ann Intern Med. 2003 Mar 4;138(5):436-7. No abstract available.

PMID:
12614104
20.

Patients with elevated liver enzymes are not at higher risk for statin hepatotoxicity.

Chalasani N, Aljadhey H, Kesterson J, Murray MD, Hall SD.

Gastroenterology. 2004 May;126(5):1287-92.

PMID:
15131789

Supplemental Content

Support Center